Loyola Initiates Comprehensive LDL Apheresis Program
Loyola Initiates Comprehensive LDL Apheresis Program
MAYWOOD, Ill. - Some patients are genetically prone to such dangerously high levels of cholesterol that no amount of diet, exercise and medications can reduce their cholesterol to safe levels.
So Loyola University Medical Center is offering a treatment called LDL apheresis, which is similar to kidney dialysis. Once every two weeks, a patient spends two to four hours connected to an apheresis unit that removes 70-80 percent of the patient’s LDL (bad) cholesterol, then returns the blood to the body. The good HDL cholesterol is not removed.
Loyola is among a handful of centers in the Midwest – and the only academic medical center in Chicago – to offer LDL apheresis.
Loyola’s multidisciplinary LDL Apheresis Program is intended for patients who have been unable to control cholesterol with lifestyle changes and medications. They include patients with coronary heart disease who have LDL cholesterol greater than 200 mg/dL, and patients without coronary artery disease who have LDL levels greater than 300 mg/dL.
About 1 in 500 people have genetic abnormalities that cause LDL cholesterol levels to be three to five times as high as normal levels. The condition, called familial hypercholesterolemia, causes heart disease at a young age.
Familial hypercholesterolemia runs in Fran Tobias’ family. Her father died of a heart attack in his early 40s, her mother had a heart attack at age 45, and two brothers died of heart disease. Tobias had her first heart attack at age 37, a second heart attack at age 45, a quintuple bypass surgery and eight stents.
Tobias, 56, who lives in Glen Ellyn, is successfully controlling her LDL by coming in for apheresis treatments at Loyola every two weeks.
“This is literally a lifesaver for me,” Tobias said. “If I were to stop, I probably would have another heart attack within 18 months to two years."
LDL apheresis is done under the guidance of medical specialists from Loyola’s transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist). The program is directed by Binh An P. Phan, MD, and Phillip J. DeChristopher, MD, PhD. Phan is director of Loyola’s Preventive Cardiology Program and DeChristopher is medical director of Transfusion Medicine and the Apheresis Center.
“The aim of the Loyola LDL Apheresis Program is to provide a multidisciplinary, specialized service for the comprehensive evaluation and treatment of patients who require LDL apheresis,” Phan said.
If you are a prospective patient and would like more information or to make an appointment, please call 888-LUHS-888 (888-584-7888).
NEWS ARCHIVES
- March 2013 (1)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- September 2012 (3)
- August 2012 (2)
- July 2012 (2)
- June 2012 (2)
- March 2012 (4)
- February 2012 (3)
- January 2012 (2)
- December 2011 (1)
- October 2011 (3)
- September 2011 (5)
- August 2011 (3)
- July 2011 (1)
- June 2011 (2)
- May 2011 (6)
- April 2011 (3)
- March 2011 (1)
- February 2011 (3)
- January 2011 (2)
- December 2010 (1)
- November 2010 (4)
- October 2010 (2)
- August 2010 (2)
- July 2010 (2)
- June 2010 (1)
- May 2010 (4)
- April 2010 (3)
- March 2010 (2)
- February 2010 (1)
- January 2010 (1)
- November 2009 (1)
- September 2009 (1)
- August 2009 (1)
- July 2009 (3)
- May 2009 (1)
- April 2009 (2)
- March 2009 (1)
- February 2009 (5)
- January 2009 (2)
- December 2008 (1)
- November 2008 (3)
More News
MEDIA RELATIONS
Media Relations
(708) 216-2445
jritter@lumc.edu
Media Relations
(708) 216-8232
adillon@lumc.edu